Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Matthew Bezzant

Physician Assistant Las Cruces, NM Physician Assistant

NPI 1578873774 CMS profile 11064494

2970 N Main St, Las Cruces, NM 88001

Open in the dashboard

General payments

$2,269

49 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Bezzant of Las Cruces, NM is reported in the CMS Open Payments database as having received $2,269 across 49 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,485 18
2024 General $188 2
2022 General $79 2
2021 General $516 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Bezzant
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Matthew Bezzant were reported at $1,485. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Matthew Bezzant Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $516 $132 $37–$438 $132
2022 $79 $155 $48–$522 $149
2023 $0 $167 $52–$557 $160
2024 $188 $178 $55–$600 $164
2025 $1,485 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Aerin Medical Inc. $1,560 18 payments
  2. Lilly USA, LLC $179 9 payments
  3. GlaxoSmithKline, LLC. $122 5 payments
  4. Genzyme Corporation $113 2 payments
  5. Pfizer Inc. $77 2 payments
  6. AstraZeneca Pharmaceuticals LP $66 5 payments
  7. Janssen Pharmaceuticals, Inc $44 2 payments
  8. Novo Nordisk Inc $36 2 payments
  9. Sanofi-Aventis U.S. LLC $33 2 payments
  10. Intersect ENT, Inc. $25 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,535 44 payments
  2. Travel and Lodging $669 4 payments
  3. Education $65 1 payment
Products named General payments · program years 2021–2025
  1. VIVAER STYLUS $1,560 18 payments
  2. RHINAER STYLUS $313 6 payments
  3. DUPIXENT $209 3 payments
  4. JARDIANCE $137 6 payments
  5. TRULICITY $137 6 payments
  6. NUCALA $94 3 payments
  7. PREVNAR 13 $77 2 payments
  8. XARELTO $44 2 payments
  9. INVOKANA $44 2 payments
  10. EMGALITY $42 3 payments
  11. Other $350 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,178

Median for Physician Assistant: 241

Drug cost

$70,410

Median for Physician Assistant: $4,110

Branded share of claims

4.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 13 $47,587
Ipratropium Bromide Generic 261 $7,992
Fluticasone Propionate Generic 166 $3,106
Omeprazole Generic 217 $2,592
Ofloxacin Generic 62 $2,472
Azelastine Hcl Generic 67 $2,285
Famotidine Generic 69 $885
Fluocinolone Acetonide Oil Generic 20 $682
Doxycycline Monohydrate Generic 25 $634
Mupirocin Generic 30 $351

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$54,750

Medicare's payments for the services billed

Medicare patients

523

Average age 75

Services billed

1,145

289 women, 234 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 31%
Ischemic heart disease 27%
Osteoporosis 24%
Depression 22%
Chronic kidney disease 20%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record